Given the fact that PSNS dysfunction is widely present and is a risk factor in various cardiovascular diseases, aging, and obesity, this drug and other BChE inhibitors may offer new opportunity to improve PSNS function in these diseases. This evidence concerns the gene BCHE and Obesity.